Status:
TERMINATED
Anecortave Acetate Risk-Reduction Trial (AART)
Lead Sponsor:
Alcon Research
Conditions:
Dry AMD
Eligibility:
All Genders
50+ years
Phase:
PHASE3
Brief Summary
A 48 month study of posterior juxtascleral administrations of Anecortave Acetate 15 or 30 mg or sham administration every 6 months.
Eligibility Criteria
Inclusion
- Dry AMD study eye, Wet AMD non-study eye.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Age
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2009
Estimated Enrollment :
2596 Patients enrolled
Trial Details
Trial ID
NCT00307398
Start Date
March 1 2004
End Date
January 1 2009
Last Update
November 28 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Study Centers in the United States and Globally
Fort Worth, Texas, United States, 76134